Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Active, not recruiting · NCT03526432 · Registry updated 2026-07-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 2 | 2026-07-30 | NCT03526432 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genentech, Inc. | 221 |
| University of Oklahoma | 146 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Stephenson Cancer Center, University of Oklahoma Health Sciences Center | Oklahoma City | United States | 3 |
| UAB Women and Infants Center | Birmingham | United States | 1 |
| Washington University School of Medicine | St Louis | United States | 26 |